[{"address1": "301-217 Queen Street West", "city": "Toronto", "state": "ON", "zip": "M5V 0R2", "country": "Canada", "website": "https://awaknlifesciences.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Mr. George  Scorsis", "age": 45, "title": "Co-founder & Chairman of the Board", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Tennyson", "title": "Co-founder, President, CEO & Director", "fiscalYear": 2023, "totalPay": 177550, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan James Held C.A., CPA, CA", "age": 37, "title": "Interim CFO, Chief Business Officer & Secretary", "yearBorn": 1986, "fiscalYear": 2023, "totalPay": 110971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D.", "title": "Chair of Pre-Clinical & Clinical Advisory Board and Chief Research Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.11, "open": 0.09, "dayLow": 0.09, "dayHigh": 0.1, "regularMarketPreviousClose": 0.11, "regularMarketOpen": 0.09, "regularMarketDayLow": 0.09, "regularMarketDayHigh": 0.1, "beta": 2.906, "forwardPE": -0.4166667, "volume": 3164, "regularMarketVolume": 3164, "averageVolume": 25973, "averageVolume10days": 12279, "averageDailyVolume10Day": 12279, "marketCap": 3873410, "fiftyTwoWeekLow": 0.0422, "fiftyTwoWeekHigh": 0.4036, "priceToSalesTrailing12Months": 2.4815266, "fiftyDayAverage": 0.0987228, "twoHundredDayAverage": 0.1460272, "currency": "USD", "enterpriseValue": 3304462, "floatShares": 31775992, "sharesOutstanding": 38734100, "heldPercentInsiders": 0.08449, "heldPercentInstitutions": 0.062280003, "bookValue": -0.025, "lastFiscalYearEnd": 1675123200, "nextFiscalYearEnd": 1706659200, "mostRecentQuarter": 1698710400, "netIncomeToCommon": -7323482, "trailingEps": -0.21, "forwardEps": -0.24, "enterpriseToRevenue": 2.117, "enterpriseToEbitda": -0.418, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "AWKNF", "underlyingSymbol": "AWKNF", "shortName": "AWAKN LIFE SCIENCES CORP", "longName": "Awakn Life Sciences Corp.", "firstTradeDateEpochUtc": 1627997400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "595fd0b1-2e29-3fed-b382-0b786bf6dbf2", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.1, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 554657, "totalCashPerShare": 0.014, "ebitda": -7910557, "quickRatio": 0.44, "currentRatio": 0.51, "totalRevenue": 1560898, "revenuePerShare": 0.059, "returnOnAssets": -1.50883, "returnOnEquity": -84.95297, "freeCashflow": -4199206, "operatingCashflow": -4529733, "revenueGrowth": -0.933, "grossMargins": -0.95402, "operatingMargins": -23.3216, "financialCurrency": "CAD", "trailingPegRatio": null}]